Neurogene Inc. ((NGNE)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Neurogene Inc. is conducting a Phase 1/2 clinical study titled ‘A Phase 1/2, Open-Label Clinical Study to Evaluate Safety, Tolerability, and Efficacy of NGN-401 in Subjects With Rett Syndrome.’ The study aims to assess the safety profile of NGN-401, a novel gene therapy, in females with typical Rett syndrome, a rare neurological disorder. This research is significant as it explores potential treatment options for a condition with limited therapeutic interventions.
The intervention being tested is NGN-401, a genetic therapy using a non-replicating, recombinant AAV9 vector carrying the full-length human MECP2 transgene. It is designed to address the genetic deficiencies associated with Rett syndrome.
The study follows an interventional design with a non-randomized, sequential intervention model. There is no masking, and the primary purpose is treatment. This straightforward design aims to ensure clear observation of the therapy’s effects.
The study began on June 1, 2023, with the primary completion and estimated completion dates yet to be announced. The last update was submitted on May 20, 2025, indicating ongoing recruitment and progress.
This update could positively impact Neurogene Inc.’s stock performance and investor sentiment, given the potential breakthrough in treating Rett syndrome. The study’s progress is crucial for the company’s standing in the competitive gene therapy market.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.